Nothing is more important than your patients. We at T2 Biosystems know that, and we have built a first-class service organization to ensure that you can depend on us to be there for you when you need to be there for them. Our commitment to service is as strong as our commitment to developing the diagnostic solutions that can save lives and reduce the costs of healthcare. To satisfy those needs, we have established a versatile, responsive service organization to deliver the personal attention that ensures the best performance of our instruments and tests — because that delivers the best care for your patients. As a nimble organization, we are able to tailor the service platform to meet your needs. This typically includes the following:
Regional staffing delivering direct service for:
Next day on-site service
Tailored installation procedures
On site staff training
Preventative maintenance protocols
Central call support center offers responsive, professional service
T2 Biosystems has done what many said could not be done. Its T2MR technology generates accurate, rapid results using direct sample analysis of whole blood without relying on blood culture. The T2Candida Panel represents how T2MR is the next breakthrough in medical diagnostics, and it has significant potential to save lives and reduce healthcare costs.
Michael Pfaller, MD, Former Chief Medical Officer, T2 Biosystems, Lexington, MA; Professor Emeritus, University of Iowa College of Medicine & College of Public Health, Iowa City, IA
What we need is a test that is 90% sensitive and 90% specific. That’s the test that makes a difference. If you’re at 90/90 then the negative predictive value is exceptional in virtually every population you use it in...that’s really clinically the most meaningful performance that we can achieve.
Cornelius J. Clancy, MD, Associate Professor of Medicine, Director, Mycology Program, University of Pittsburgh, Pittsburgh, PA
The ability to determine the presence or absence of Candida within hours – compared to days – is paradigm changing for patients at risk for these infections.
Eleftherios Mylonakis, MD, PhD, FIDSA, Chief, Division of Infectious Diseases, Rhode Island Hospital and The Miriam Hospital and Dean's Professor of Medical Science, Alpert Medical School of Brown University, Providence, RI
Canon US Life Sciences
We believe combining our collective expertise with T2 Biosystems' proprietary T2MR platform may enable us to develop a fully differentiated diagnostic panel for the detection of Lyme disease, an area of critical need where delays in providing appropriate treatment to patients can result in significant morbidity and unnecessary costs.
Akiko Tanaka, President and CEO of Canon U.S. Life Sciences